 |
 |
|
FROM LEFT TO RIGHT:
Jack Levy, David Woodhouse, Robert King, Claire Levy, Christiana Stamoulis, Lorence Kim |
|
biogen, inc.
As sole financial advisor to Biogen, Goldman Sachs helped execute the largest-ever merger between independent biotech firms, creating Biogen Idec Inc., the world's third-largest biotechnology company.
Biogen and IDEC, each of which had a critical “blockbuster” drug fueling its future growth, saw a merger as an opportunity to create a biotechnology company with a broader product portfolio and a deeper pipeline. The new company expects to benefit from its significant clinical development and global marketing capabilities in both oncology and immunology.
The companies combined in a carefully crafted merger of equals that capitalized on their complementary strengths and preserved strong relationships with their licensing partners.
|
 |
4 / 4 |
|
